What This Bill Does
This bill would direct the National Institutes of Health and the Department of Health and Human Services to evaluate hormone variability and hormone testing in women experiencing perimenopause. It focuses on a stage of life that can bring irregular cycles, hot flashes, sleep disruption, mood changes, and other symptoms that are often hard to measure with standard tests. The measure would affect women approaching menopause, clinicians who treat them, and researchers studying women’s health. It does not create a new benefit or payment program; instead, it sets a federal research and evaluation mandate for NIH and HHS.
- Directs NIH to evaluate hormone variability in women with perimenopause.
- Directs HHS to evaluate hormone testing for women in perimenopause.
- Focuses on a common midlife health transition that can be hard to diagnose.
- Creates a federal research and review mandate, not a new insurance benefit.
Who This Bill Affects
For the general public, this bill would not immediately change coverage or benefits, but it could shape how doctors evaluate perimenopause symptoms and whether hormone tests are used more consistently. Women experiencing perimenopause are the main group affected, since the bill targets federal review of hormone variability and testing during that life stage.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Women experiencing perimenopause Supporters say the bill could lead to better recognition of symptoms that are often dismissed or misattributed. A stronger evidence base may help patients get more accurate answers and more tailored care.
- Primary care doctors and gynecologists Clinicians may welcome clearer federal guidance on when hormone testing is useful and how to interpret fluctuating results. That could reduce guesswork and improve consistency in treatment decisions.
- Women’s health researchers Researchers often argue that perimenopause has not received enough focused study compared with other stages of reproductive health. A federal evaluation can help identify gaps and set priorities for future research.
- Budget-conscious lawmakers Some may question whether a new federal evaluation is the best use of agency time and resources when NIH and HHS already have many competing research and oversight responsibilities. They may prefer funding direct care or broader women’s health initiatives instead.
- Clinicians wary of overtesting Some health professionals may worry that emphasizing hormone testing could encourage unnecessary lab work for a condition that is often diagnosed clinically. They may argue that symptoms and patient history matter more than hormone levels that naturally fluctuate.
- Health policy skeptics Critics may say a study mandate could produce reports without changing real-world care unless Congress follows up with implementation. They may view it as a modest step that risks raising expectations faster than the health system can respond.
Key Implications
-
““evaluate hormone variability””
This directs NIH to examine how hormone levels change during perimenopause and whether those changes can be measured reliably. The practical effect is to push federal research toward better understanding of a stage that is often clinically messy and variable.
-
““evaluate hormone testing””
This asks HHS to review whether current hormone tests are useful for women in perimenopause. That could affect future clinical guidance on when testing helps and when it may not add much value.
-
““in women with respect to perimenopause””
The focus is specifically on women going through the menopausal transition, not on menopause broadly or on all hormone-related conditions. That narrows the policy to a large but specific patient population.
-
““Director of the National Institutes of Health””
NIH involvement signals a research and evidence-building approach rather than an immediate change in benefits or coverage. Any downstream effect would likely come through studies, reports, or later guidance.
-
““Secretary of Health and Human Services””
HHS involvement suggests the bill could influence federal health policy and clinical recommendations beyond research alone. In practice, that can shape how providers and patients understand testing and symptom evaluation.
Latest Status
May 29, 2026
Referred to the House Committee on Energy and Commerce.
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.